NCT06362590Available不适用
Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
- Seagen Inc.
研究概览
简要总结
The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Approved For Marketing
不适用
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)SARS-CoV2 InfectionNCT04323761Gilead Sciences
Approved For Marketing
不适用
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) DaratumumabNCT04264884Janssen Research & Development, LLC
已完成
3 期
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)Crohn's DiseaseNCT00338650Abbott1,000
Temporarily Not Available
不适用
Expanded Access to Telisotuzumab VedotinNon-Small Cell Lung Cancer (NSCLC)NCT04830202AbbVie
已完成
不适用
AN OPEN-LABEL, MULTI-CENTER, EXPANDED ACCESS STUDY OF TRASTUZUMAB DERUXTECAN IN JAPANESE SUBJECTS WITH HER2-POSITIVE ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMAJPRN-jRCT2080225138DAIICHI SANKYO Co.,Ltd.64